Clinical Use of Lymphocyte Subset Analysis: As a Prognostic Marker for Dogs with Pyometra

Abstract

BackgroundLymphocyte subset analysis is clinically applied in human medicine. However, lymphocyte subset analysis is rarely used in small animal practice. We hypothesized that lymphocyte subsets analysis was useful in small animal practice as a biomarker for evaluating immune competence and predicting the disease prognosis. Lymphocyte subset analysis was performed prospectively for pyometra, a common disease in dogs, to assess its clinical usefulness in small animal practice.ResultsThis study included 29 dogs diagnosed with pyometra. They were classified into group 1 and group 2 on the basis of clinical course postoperatively. Sixteen dogs were classified in group 1 with no adverse events postoperatively. Thirteen dogs experienced adverse events such as increase in C-reactive protein concentration and white blood cell count, discharge from operation site, and hypoglycemia. These dogs were classified as group 2. Nine dogs were below the reference interval for the lymphocyte subset, eight of which were in group 2. Group 2 included significantly more dogs with lymphocyte subset abnormalities (p = 0.005). In the multivariable logistic regression analysis, only the result of lymphocyte subset analysis was significantly associated with adverse events (p = 0.02, 95% confidence interval = 1.68–192). Most dogs in group 2 were successfully treated.ConclusionsThese results indicate that lymphocyte subset analysis is useful as a prognostic tool for pyometra. Further studies are necessary for evaluating the clinical usefulness of lymphocyte subset analysis in pyometra and other diseases.